Follicular Lymphoma | Clinical

European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma

June 12, 2022

The European Commission has granted a conditional marketing authorization to mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 prior systemic therapies

Bispecific Antibody Triplet Regimen Induces 100% Response Rate in R/R FL

June 04, 2022

Findings from an arm of the EPCORE NHL-2 trial, presented at the 2022 ASCO Annual meeting, showed promising antitumor activity in patients with relapsed or refractory follicular lymphoma on subcutaneous epcoritamab combined with rituximab and lenalidomide.

Comparable Efficacy Profile Shown in Axi-cel and Tisa-Cel in Follicular Lymphoma

April 25, 2022

Match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in the ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar outcomes in regard to efficacy between the 2 cellular therapies.